SEARCH

SEARCH BY CITATION

References

  • 1
    Wahlberg T, Blombäck M, Hall P, Axelsson G: Application of indicators, predictors, and diagnostic indices in coagulation disorders. Methods Inf Med 19: 194200, 1980.
  • 2
    Parkin JD, Smith IL, O'Neill AI, Ibrahim KMA, Butcher LA: Mild bleeding disorders. A clinical, and laboratory study. Med J Aust 156: 614617, 1992.
  • 3
    Chimbira TH, Anderson ABM, Turnbull AC: Relation between measured menstrual blood loss, and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight, and endometrial surface area. Br J Obstet Gynaecol 87: 603609, 1980.
  • 4
    Fraser IS, Pearse C, Shearman RP, Elliott PM, McIlveen JRM: Efficacy of mefanamic acid in patients with a complaint of menorrhagia. Obstet Gynecol 58: 543551, 1981.
  • 5
    Fraser IS, McCarron G, Markham R: A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol 149: 788793, 1984.
  • 6
    Granleese J: Personality, sexual behavior, and menstrual symptoms: Their relevance to clinically presenting menorrhagia. Person Individ Differ 11: 379390, 1990.
  • 7
    Edlund M, Magnusson C, von Schoultz B: Quality of life—A Swedish survey of 2200 women. In SmithSK (ed): “Dysfunctional Uterine Bleeding.” London: The Royal Society of Medicine Press Ltd., 1994, pp 3637.
  • 8
    Greer IA, Lowe GDO, Walker JJ, Forbes CD: Haemorrhagic problems in obstetrics, and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 98: 909918, 1991.
  • 9
    Edlund M, Andersson K, Rybo G, Lindoff C, Åstedt B, von Schoultz B: Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol 102: 913917, 1995.
  • 10
    Hallberg L, Nilsson L: Determination of menstrual blood loss. Scand J Clin Lab Invest 16: 244248, 1964.
  • 11
    Mielke CH, Kaneshiro MM, Maher JA, Weiner JM, Rapaport SJ: The standardized normal bleeding time, and its prolongation by aspirin. Blood 34: 204215, 1969.
  • 12
    Rosén S, Andersson M, Blombäck M, Hägglund U, Larrieu MJ, Wolf M, Boyer C, Rothschild C, Nilsson IM, Sjörin E, Winazzer H: Clinical applications of a chromogenic substrate method for determination of factor VIII activity. Thromb Haemost 54: 818823, 1985.
  • 13
    Bergström K, Egberg N: Determination of vitamin-K sensitive coagulation factors in plasma. Studies on three methods using synthetic chromogenic substrates. Thromb Res 12: 531547, 1978.
  • 14
    Teger-Nilsson AC, Friberger P, Gyzander E: Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin-specific tripeptide substrate. Scand J Clin Lab Invest 37: 403409, 1977.
  • 15
    Silveira AMV, Yamahoto T, Adamsson L, Hessel B, Biombäck B: Application of an enzyme-linked immuno-sorbent assay (ELISA) to von Willebrand factor (vWF), and its derivatives. Thromb Res 43: 91102, 1986.
  • 16
    Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN: Measurement of crosslinked fibrin degradation products—An immunoassay using monoclonal antibodies. Thromb Haemost 50: 591, 1983.
  • 17
    Vermylen C, de Vreker RA, Verstraete M: A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT Test). Clin Chim Acta 8: 418424, 1963.
  • 18
    Wahlberg TB, Blombäck M, Ruggeri ZM: Differences between heterozygous dominant, and recessive von Willebrand's disease type I expressed by bleeding symptoms, and combination of factor VIII variables. Thromb Haemost 50: 864868, 1983.
  • 19
    Anvret M, Blombäck M, Lindstedt M, Söderlind E, Tapper-Persson M, Thelander A-C: Genetic, and blood coagulation characterization of “Swedish” families with von Willebrand's disease types I, and III: New aspects of heredity. Hum Genet 89: 147154, 1992.
  • 20
    Blombäck M, Eneroth P, Andersson O, Anvret M: On laboratory problems in diagnosing mild von Willebrand's disease. Am J Hematol 40: 117120, 1992.
  • 21
    Zhang Z, Lindstedt M, Blombäck M, Anvret M: Effects of the mutant von Willebrand factor gene in von Willebrand disease. Hum Genet 96: 388394, 1995.
  • 22
    Rodeghiero F, Castaman G, Dini E: Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 69: 454459, 1987.
  • 23
    Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shultz J, Abshire TC: Prevalence of von Willebrand disease in children: A multiethnic study. J Pediatr 123: 893898, 1993.
  • 24
    Blombäck M, Eneroth P, Landgren B-M, Lagerström M, Andersson O: On the intraindividual, and gender variability of haemostatic components. Thromb Haemost 67: 7075, 1992.
  • 25
    Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS: Serial studies in von Willebrand's disease: Variability versus “variants.” Blood 56: 712716, 1980.
  • 26
    Mandalaki T, Louizou C, Dmitriadou C, Symeonides PH: Variations in factor VIII during the menstrual cycle in normal women. N Engl J Med 302: 1093, 1980.